Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Giuseppe Gaetano Loscocco, Moazah Iftikhar, Masooma S Rana, Omer Karrar, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Natasha Szuber, Tiziano Barbui, Paola Guglielmelli, Alessandro Maria Vannucchi, Cinthya Zepeda Mendoza, Kaaren K. Reichard, Rong He, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6621.

https://doi.org/10.1182/blood-2024-193373

Published: 2024

Journal Articles

Revised International Working Group Risk Model for Survival in Polycythemia Vera

Ayalew Tefferi, Giuseppe Gaetano Gaetano Loscocco, Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Alessandro Atanasio, Fiorenza Vanderwert, Alessio Enderti, Animesh D. Pardanani, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro Maria Vannucchi

Blood (2024) 144 (Supplement 1): 1785.

https://doi.org/10.1182/blood-2024-193118

Published: 2024

Journal Articles

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

John O. Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Maria Vannucchi, Tymara Berry, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 1808.1.

https://doi.org/10.1182/blood-2024-199235

Published: 2024

Journal Articles

Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Paola Guglielmelli, Chiara Maccari, Manjola Balliu, Giuseppe Gaetano Loscocco, Naseema Gangat, Alessandro Atanasio, Paolo Cicogna, Leonardo Signori, Giada Rotunno, Niccolò Bartalucci, Gloria Nanni, Anna Catelani, Rossella Manfredini, Chiara Paoli, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 144 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2024-198891

Published: 2024

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Naseema Gangat, Giuseppe Gaetano Loscocco, Patricia Carey, Priyansh Faldu, Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Animesh D. Pardanani, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Alessandro Maria Vannucchi, Ayalew Tefferi, Paola Guglielmelli

Blood (2024) 144 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2024-204138

Published: 2024

Journal Articles

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Blood (2024) 144 (Supplement 1): 997.

https://doi.org/10.1182/blood-2024-201729

Published: 2024

Journal Articles

Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities

Fnu Aperna, Moazah Iftikhar, Masooma S Rana, Animesh D. Pardanani, Paola Guglielmelli, Alessandro Maria Vannucchi, Naseema Gangat, Ayalew Tefferi, Giuseppe Gaetano Loscocco

Blood (2024) 144 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2024-203394

Published: 2024

Journal Articles

Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab

Austin G. Kulasekararaj, Jaroslaw Czyz, Catherine Flynn, Gabriela Roncone Gastal, Marek Hus, Chrysavgi Lalayanni, Erfan Nur, Phillip Scheinberg, Yasutaka Ueda, Alessandro Maria Vannucchi, Maria Vidriales Vicente, Iige Viigimaa, Simon Buatois, Alice C. Chang, Sammy Chebon, Alexander Röth

Blood (2024) 144 (Supplement 1): 1323.

https://doi.org/10.1182/blood-2024-200400

Published: 2024

Journal Articles

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Blood (2024) 144 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2024-204693

Published: 2024

Journal Articles

Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors

Giuseppe Gaetano Loscocco, Fnu Aperna, Moazah Iftikhar, Masooma S Rana, Amritpal Singh, Tiziano Barbui, Paola Guglielmelli, Alessandro Maria Vannucchi, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2024-200229

Published: 2024

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Journal Articles

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2023) 142 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2023-174076

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Claire N Harrison, Alessandro Maria Vannucchi, Christian Recher, Francesco Passamonti, Aaron T. Gerds, Juan Carlos Hernandez Boluda, Abdulraheem Yacoub, Shireen Sirhan, Jun Kawashima, Bharat Patel, Bryan Strouse, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2023-178816

Published: 2023

Journal Articles

A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy

Barbara Mora, Giacomo Pellegrini, Matteo Franchi, Olivia Leoni, Daniela D'Ippoliti, Valeria Di Fabrizio, Fabrizio Gemmi, Claudia Szasz, Margherita Maffioli, Carmelo Gurnari, Enrico Attardi, Giovanni Corrao, Paola Guglielmelli, Maria Teresa Voso, Alessandro Maria Vannucchi, Francesco Passamonti

Blood (2023) 142 (Supplement 1): 4572.

https://doi.org/10.1182/blood-2023-182107

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Blood (2023) 142 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2023-186429

Published: 2023

Journal Articles

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2023-184845

Published: 2023

NARROW

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Revised International Working Group Risk Model for Survival in Polycythemia Vera

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities

Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors

CALR mutation burden in essential thrombocythemia and disease outcome

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only